GLI3

Across TCGA pan-cancer cohorts, GLI3 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated GLI3 data layer compared with 26 for mass-spec protein and 10 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher GLI3 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated GLI3 expression acts as an unfavorable survival marker.

PDAC, LSCC, and LUAD are the cancer types where GLI3 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Tertile	All	0.160	1.000	.024	12	view →
LSCC	DFS	Quartile	II,III,IV	0.511	0.848	.049	2	view →
LUAD	OS	Median	III,IV	0.241	0.738	.027	2	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

GLI3–PDAC (OS)

Open the PDAC breakdown →